SCHEMBL12848792

SCHEMBL12848792

COc1cc(-c2cn3cccc(OC)c3n2)ccc1OCc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.62
ALDH1A3 P47895 3/20 0.52
HRH3 Q9Y5N1 2/20 0.52
ALDH1A1 P00352 7/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
RAB9A P51151 6/20 0.49
KDM4E B2RXH2 6/20 0.49
MAPT P10636 6/20 0.49
NPC1 O15118 5/20 0.49
NFKB1 P19838 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RECQL P46063 1/20 0.49
HPGD P15428 4/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 2/20 0.49
PKM P14618 2/20 0.48
TP53 P04637 3/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848931 0.95 PPARG (0.61) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL12797512 0.92 PPARG (0.60) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL12848981 0.92 HRH3 (0.62) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL12848910 0.91 PPARG (0.54) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL12848794 0.90 PPARG (0.57) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL15374937 0.88 PPARG (0.59) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL6527793 0.85 RAB9A (0.68) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2
SCHEMBL12848932 0.85 PPARG (0.56) PPARGHRH3ALDH1A1SMN1; SMN2RAB9A
SCHEMBL12848878 0.84 KDM4E (0.62) ALDH1A1SMN1; SMN2RAB9AKDM4EMAPT
SCHEMBL12848984 0.84 ALDH1A1 (0.53) PPARGALDH1A3HRH3ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE PPARG 22/4885ALDH1A3 771/4885HRH3 2016/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE PPARG 25/4885ALDH1A3 797/4885HRH3 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.